Date: 2013-08-20
Type of information: Grant
Company: Somantix (The Netherlands) the University of Birmingham (UK)
Investors: European Industrial Doctorate (EU)
Amount: €1.5 million
Funding type: grant
Planned used: the grant will be used for research into new antibodies that will destroy a tumour\'s blood vessels and eradicate the tumour.
Others: * On August 20, 2013, the European Commission has awarded its 50th European Industrial Doctorate (EID) research grant. This €1.5 million grant is for research into new antibodies that will destroy a tumour\'s blood vessels and eradicate the tumour. The so-called VAMPIRE project (\'Vascular Antibody-Mediated Pharmaceutically Induced tumour Resection\') is led by the University of Birmingham in the UK and SomantiX, a Dutch biotech company based in Utrecht. The research is supported by associated European universities, companies and research centres including Swiss science and technology university ETH Zurich and the charity Cancer Research UK. EuroTransBio grant.
Two years ago, a grant of € 1.5 million has been awarded to a multidisciplinary consortium including SomantiX and the VU University Medical Center Amsterdam by the European collaborative ETB program. The subsidy is for a three year period and will allow design and development of small molecules for the inhibition of tumor angiogenesis in colon cancer.
Therapeutic area: Cancer - Oncology
